The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hyperimmune Globulins Market Research Report 2025
Synopsis
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The global Hyperimmune Globulins market was valued at US$ 1693 million in 2023 and is anticipated to reach US$ 2733.7 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%.
Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent.
In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.
This report aims to provide a comprehensive presentation of the global market for Hyperimmune Globulins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperimmune Globulins.
Report Scope
The Hyperimmune Globulins market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hyperimmune Globulins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hyperimmune Globulins manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segment by Application
Government Institutions
Private Sector
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hyperimmune Globulins in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The global Hyperimmune Globulins market was valued at US$ 1693 million in 2023 and is anticipated to reach US$ 2733.7 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%.
Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent.
In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.
This report aims to provide a comprehensive presentation of the global market for Hyperimmune Globulins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperimmune Globulins.
Report Scope
The Hyperimmune Globulins market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hyperimmune Globulins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hyperimmune Globulins manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Segment by Type
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Segment by Application
Government Institutions
Private Sector
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hyperimmune Globulins in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Hyperimmune Globulins Market Overview
1.1 Product Overview and Scope of Hyperimmune Globulins
1.2 Hyperimmune Globulins Segment by Type
1.2.1 Global Hyperimmune Globulins Market Value Comparison by Type (2024-2030)
1.2.2 Hepatitis B Immunoglobulins
1.2.3 Rabies Immunoglobulins
1.2.4 Tetanus Immunoglobulins
1.2.5 Rho(D) Immunoglobulins
1.2.6 Other
1.3 Hyperimmune Globulins Segment by Application
1.3.1 Global Hyperimmune Globulins Market Value by Application: (2024-2030)
1.3.2 Government Institutions
1.3.3 Private Sector
1.3.4 Other
1.4 Global Hyperimmune Globulins Market Size Estimates and Forecasts
1.4.1 Global Hyperimmune Globulins Revenue 2019-2030
1.4.2 Global Hyperimmune Globulins Sales 2019-2030
1.4.3 Global Hyperimmune Globulins Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Hyperimmune Globulins Market Competition by Manufacturers
2.1 Global Hyperimmune Globulins Sales Market Share by Manufacturers (2019-2024)
2.2 Global Hyperimmune Globulins Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Hyperimmune Globulins Average Price by Manufacturers (2019-2024)
2.4 Global Hyperimmune Globulins Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hyperimmune Globulins, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hyperimmune Globulins, Product Type & Application
2.7 Hyperimmune Globulins Market Competitive Situation and Trends
2.7.1 Hyperimmune Globulins Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Hyperimmune Globulins Players Market Share by Revenue
2.7.3 Global Hyperimmune Globulins Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hyperimmune Globulins Retrospective Market Scenario by Region
3.1 Global Hyperimmune Globulins Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Hyperimmune Globulins Global Hyperimmune Globulins Sales by Region: 2019-2030
3.2.1 Global Hyperimmune Globulins Sales by Region: 2019-2024
3.2.2 Global Hyperimmune Globulins Sales by Region: 2025-2030
3.3 Global Hyperimmune Globulins Global Hyperimmune Globulins Revenue by Region: 2019-2030
3.3.1 Global Hyperimmune Globulins Revenue by Region: 2019-2024
3.3.2 Global Hyperimmune Globulins Revenue by Region: 2025-2030
3.4 North America Hyperimmune Globulins Market Facts & Figures by Country
3.4.1 North America Hyperimmune Globulins Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Hyperimmune Globulins Sales by Country (2019-2030)
3.4.3 North America Hyperimmune Globulins Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hyperimmune Globulins Market Facts & Figures by Country
3.5.1 Europe Hyperimmune Globulins Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Hyperimmune Globulins Sales by Country (2019-2030)
3.5.3 Europe Hyperimmune Globulins Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hyperimmune Globulins Market Facts & Figures by Country
3.6.1 Asia Pacific Hyperimmune Globulins Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Hyperimmune Globulins Sales by Country (2019-2030)
3.6.3 Asia Pacific Hyperimmune Globulins Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hyperimmune Globulins Market Facts & Figures by Country
3.7.1 Latin America Hyperimmune Globulins Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Hyperimmune Globulins Sales by Country (2019-2030)
3.7.3 Latin America Hyperimmune Globulins Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hyperimmune Globulins Market Facts & Figures by Country
3.8.1 Middle East and Africa Hyperimmune Globulins Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Hyperimmune Globulins Sales by Country (2019-2030)
3.8.3 Middle East and Africa Hyperimmune Globulins Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hyperimmune Globulins Sales by Type (2019-2030)
4.1.1 Global Hyperimmune Globulins Sales by Type (2019-2024)
4.1.2 Global Hyperimmune Globulins Sales by Type (2025-2030)
4.1.3 Global Hyperimmune Globulins Sales Market Share by Type (2019-2030)
4.2 Global Hyperimmune Globulins Revenue by Type (2019-2030)
4.2.1 Global Hyperimmune Globulins Revenue by Type (2019-2024)
4.2.2 Global Hyperimmune Globulins Revenue by Type (2025-2030)
4.2.3 Global Hyperimmune Globulins Revenue Market Share by Type (2019-2030)
4.3 Global Hyperimmune Globulins Price by Type (2019-2030)
5 Segment by Application
5.1 Global Hyperimmune Globulins Sales by Application (2019-2030)
5.1.1 Global Hyperimmune Globulins Sales by Application (2019-2024)
5.1.2 Global Hyperimmune Globulins Sales by Application (2025-2030)
5.1.3 Global Hyperimmune Globulins Sales Market Share by Application (2019-2030)
5.2 Global Hyperimmune Globulins Revenue by Application (2019-2030)
5.2.1 Global Hyperimmune Globulins Revenue by Application (2019-2024)
5.2.2 Global Hyperimmune Globulins Revenue by Application (2025-2030)
5.2.3 Global Hyperimmune Globulins Revenue Market Share by Application (2019-2030)
5.3 Global Hyperimmune Globulins Price by Application (2019-2030)
6 Key Companies Profiled
6.1 CSL Behring
6.1.1 CSL Behring Corporation Information
6.1.2 CSL Behring Description and Business Overview
6.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.1.4 CSL Behring Hyperimmune Globulins Product Portfolio
6.1.5 CSL Behring Recent Developments/Updates
6.2 Grifols
6.2.1 Grifols Corporation Information
6.2.2 Grifols Description and Business Overview
6.2.3 Grifols Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Grifols Hyperimmune Globulins Product Portfolio
6.2.5 Grifols Recent Developments/Updates
6.3 Biotest
6.3.1 Biotest Corporation Information
6.3.2 Biotest Description and Business Overview
6.3.3 Biotest Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Biotest Hyperimmune Globulins Product Portfolio
6.3.5 Biotest Recent Developments/Updates
6.4 Kedrion
6.4.1 Kedrion Corporation Information
6.4.2 Kedrion Description and Business Overview
6.4.3 Kedrion Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kedrion Hyperimmune Globulins Product Portfolio
6.4.5 Kedrion Recent Developments/Updates
6.5 CBPO
6.5.1 CBPO Corporation Information
6.5.2 CBPO Description and Business Overview
6.5.3 CBPO Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.5.4 CBPO Hyperimmune Globulins Product Portfolio
6.5.5 CBPO Recent Developments/Updates
6.6 Emergent (Cangene)
6.6.1 Emergent (Cangene) Corporation Information
6.6.2 Emergent (Cangene) Description and Business Overview
6.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Emergent (Cangene) Hyperimmune Globulins Product Portfolio
6.6.5 Emergent (Cangene) Recent Developments/Updates
6.7 Kamada
6.6.1 Kamada Corporation Information
6.6.2 Kamada Description and Business Overview
6.6.3 Kamada Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kamada Hyperimmune Globulins Product Portfolio
6.7.5 Kamada Recent Developments/Updates
6.8 CNBG
6.8.1 CNBG Corporation Information
6.8.2 CNBG Description and Business Overview
6.8.3 CNBG Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.8.4 CNBG Hyperimmune Globulins Product Portfolio
6.8.5 CNBG Recent Developments/Updates
6.9 Hualan Bio
6.9.1 Hualan Bio Corporation Information
6.9.2 Hualan Bio Description and Business Overview
6.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hualan Bio Hyperimmune Globulins Product Portfolio
6.9.5 Hualan Bio Recent Developments/Updates
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Corporation Information
6.10.2 Shanghai RAAS Description and Business Overview
6.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Shanghai RAAS Hyperimmune Globulins Product Portfolio
6.10.5 Shanghai RAAS Recent Developments/Updates
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Corporation Information
6.11.2 Sichuan Yuanda Shuyang Hyperimmune Globulins Description and Business Overview
6.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments/Updates
6.12 ADMA Biologics
6.12.1 ADMA Biologics Corporation Information
6.12.2 ADMA Biologics Hyperimmune Globulins Description and Business Overview
6.12.3 ADMA Biologics Hyperimmune Globulins Sales, Revenue and Gross Margin (2019-2024)
6.12.4 ADMA Biologics Hyperimmune Globulins Product Portfolio
6.12.5 ADMA Biologics Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hyperimmune Globulins Industry Chain Analysis
7.2 Hyperimmune Globulins Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hyperimmune Globulins Production Mode & Process
7.4 Hyperimmune Globulins Sales and Marketing
7.4.1 Hyperimmune Globulins Sales Channels
7.4.2 Hyperimmune Globulins Distributors
7.5 Hyperimmune Globulins Customers
8 Hyperimmune Globulins Market Dynamics
8.1 Hyperimmune Globulins Industry Trends
8.2 Hyperimmune Globulins Market Drivers
8.3 Hyperimmune Globulins Market Challenges
8.4 Hyperimmune Globulins Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
